The value of Gd-EOB-DTPA-enhanced MRI in the differential diagnosis of HCC with hyperintensity on HBP and FNH

Gd-EOB-DTPA增强MRI在肝胆期高信号肝细胞癌与局灶性结节性增生鉴别诊断中的价值

阅读:1

Abstract

The aim was to investigate the differential diagnostic potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) features and establish a nomogram model for distinguishing hepatocellular carcinoma (HCC) from focal nodular hyperplasia (FNH) presenting with hyperintensity on the hepatobiliary phase (HBP). This retrospective study enrolled 80 patients with pathologically confirmed HCC or FNH who underwent Gd-EOB-DTPA-enhanced MRI between January 2017 and December 2020. All lesions exhibited hyperintensity on HBP. Morphological characteristics, signal patterns, and apparent diffusion coefficient (ADC) values were analyzed. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of HCC, adjusting for age and sex. A diagnostic nomogram was subsequently constructed. After adjusting for age and sex, the study showed that nodule-in-nodule hyperintensity on HPB (odds ratio [OR] = 36.46, 95% confidence interval [CI]: 4.01-331.13), an ADC value ≤1.087 × 10-3 mm2/s (OR = 0.004, 95% CI: 0.00-0.06), and the absence of a central scar (OR = 0.04, 95% CI: 0.003-0.40) were independent predictors of HCC. The nomogram incorporating these predictors demonstrated excellent diagnostic performance, with an area under the receiver operating characteristic curve of 0.933 (95% CI: 0.874-0.991). The calibration curve showed optimal agreement between predicted and observed probabilities. Gd-EOB-DTPA-enhanced MRI characteristics combined with ADC values enable reliable differentiation between HBP-hyperintense HCC and FNH. The proposed nomogram model provides a clinically applicable tool for improving diagnostic accuracy in challenging cases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。